FDA Warns Orlistat Weight-Loss Drug Linked to Kidney Stones and Acute Kidney Injury

The FDA has updated safety labeling for all orlistat-containing products following a review linking the widely used OTC weight-loss drug to rare but potentially serious kidney complications. This matters for the large number of health-conscious adults using orlistat as part of a weight management strategy, as kidney function is a critical biomarker for long-term healthspan and longevity.

The FDA's review of its Adverse Event Monitoring System and published medical literature identified 12 cases of kidney complications between orlistat's 2007 approval and December 2023. Cases included acute kidney injury, oxalate nephropathy, and calcium oxalate kidney stones. Eight patients required hospitalization and five required dialysis — outcomes that underscore the severity of even rare events. Median patient age was 61 and median drug exposure before injury was just 2.5 months.

Orlistat works by inhibiting lipase enzymes, reducing dietary fat absorption by up to 30%. The proposed mechanism for kidney harm involves increased intestinal oxalate absorption when fat is unabsorbed, since fat binds calcium that would otherwise neutralize oxalate in the gut. Excess oxalate then reaches the kidneys, potentially forming stones or causing direct tissue damage.

Notably, the FDA found the risk appears non-dose-dependent, as the difference in fat inhibition between the 60 mg OTC and 120 mg prescription doses is only 5%. This means lower-dose users are not meaningfully protected. Several affected patients had pre-existing conditions such as diabetes, hypertension, and prior kidney disease, suggesting heightened vulnerability in those populations.

Practically, anyone currently using orlistat should monitor for warning signs including back or groin pain, painful or bloody urination, leg swelling, or reduced urination frequency. Those with kidney disease history should consult a physician before continuing use. While the absolute number of identified cases is small, underreporting to the FDA is common, meaning true incidence may be higher than current data reflects.